MX2017006594A - Proteinas y congujados proteinicos con efecto hidrofobo aumentado. - Google Patents
Proteinas y congujados proteinicos con efecto hidrofobo aumentado.Info
- Publication number
- MX2017006594A MX2017006594A MX2017006594A MX2017006594A MX2017006594A MX 2017006594 A MX2017006594 A MX 2017006594A MX 2017006594 A MX2017006594 A MX 2017006594A MX 2017006594 A MX2017006594 A MX 2017006594A MX 2017006594 A MX2017006594 A MX 2017006594A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- peg conjugate
- proteins
- increased hydrophobicity
- protein conjugates
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 229920001223 polyethylene glycol Polymers 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 230000002209 hydrophobic effect Effects 0.000 abstract 2
- 239000012460 protein solution Substances 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 239000012074 organic phase Substances 0.000 abstract 1
- 239000006174 pH buffer Substances 0.000 abstract 1
- 230000005588 protonation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Algunos ejemplos pueden incluir un método para hacer una sal de conjugado de proteínas pegiladas con efecto hidrófobo aumentado. El método puede incluir proporcionar una disolución proteínica acuosa. Esta solución proteínica acuosa puede incluir una proteína y un amortiguador de pH. El método puede también incluir la reacción de un polietilenglicol con la proteína para formar un conjugado de proteínas pegiladas. El método puede incluir además la protonación de un grupo amino en el conjugado de proteínas pegiladas con un ácido orgánico hidrofábico en una fase orgánica. La protonación puede formar la sal de conjugado de proteínas pegiladas que tiene un anión hidrófobo que aumenta el efecto hidrófobo de la sal de conjugado de proteínas pegiladas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462086294P | 2014-12-02 | 2014-12-02 | |
US14/954,591 US10046058B2 (en) | 2014-12-02 | 2015-11-30 | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
US14/954,701 US20160151511A1 (en) | 2014-12-02 | 2015-11-30 | Proteins and protein conjugates with increased hydrophobicity |
PCT/US2015/063102 WO2016089818A1 (en) | 2014-12-02 | 2015-12-01 | Proteins and protein conjugates with increased hydrophobicity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017006594A true MX2017006594A (es) | 2017-09-01 |
Family
ID=56078492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017006594A MX2017006594A (es) | 2014-12-02 | 2015-12-01 | Proteinas y congujados proteinicos con efecto hidrofobo aumentado. |
Country Status (11)
Country | Link |
---|---|
US (3) | US10046058B2 (es) |
EP (2) | EP3695831A1 (es) |
JP (1) | JP2017536387A (es) |
KR (1) | KR20170086049A (es) |
CN (1) | CN106999443A (es) |
AU (1) | AU2015355180A1 (es) |
BR (1) | BR112017011531A2 (es) |
CA (1) | CA2966207A1 (es) |
MX (1) | MX2017006594A (es) |
RU (1) | RU2712644C2 (es) |
WO (1) | WO2016089818A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
US10046058B2 (en) * | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
US20180271792A1 (en) * | 2017-03-23 | 2018-09-27 | Rezolute, Inc. | Oral delivery of physiologically active substances |
US11267863B2 (en) | 2018-01-19 | 2022-03-08 | Pepgene Inc. | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same |
CN108465104A (zh) * | 2018-03-07 | 2018-08-31 | 佛山实瑞先导材料研究院(普通合伙) | 一种生长激素控释包衣及其制备方法 |
CN109493923B (zh) * | 2018-12-18 | 2021-07-30 | 赣南师范大学 | 计算化合物在水和任意溶剂中分配常数的方法 |
WO2020251003A1 (ja) * | 2019-06-14 | 2020-12-17 | 株式会社ダイセル | 液体クロマトグラフィーによるアミンの分離方法 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US362777A (en) * | 1887-05-10 | Two-wheeled vehicle | ||
US114835A (en) * | 1871-05-16 | Improvement in scroll-sawing machines | ||
US895013A (en) * | 1907-07-13 | 1908-08-04 | Charles F Hanington | Transom-operating mechanism. |
US2189363A (en) * | 1938-04-11 | 1940-02-06 | Kalous Mieczyslaw Joseph | Process and apparatus for working up nitrous gases to nitric acid |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2433883C2 (de) * | 1973-07-20 | 1986-03-27 | Research Corp., New York, N.Y. | Verwendung von physiologisch aktiven Polypeptiden |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
CA2312190A1 (en) | 1997-12-05 | 1999-06-17 | Eli Lilly And Company | Glp-1 formulations |
WO1999045964A1 (en) | 1998-03-12 | 1999-09-16 | Shearwater Polymers, Incorporated | Poly(ethylene glycol) derivatives with proximal reactive groups |
DE19932157A1 (de) * | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln |
US6323311B1 (en) | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
ES2382636T3 (es) * | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Método para producir composiciones para la administración mejorada de moléculas bioactivas |
AU2001298061A1 (en) | 2000-12-13 | 2003-07-09 | Purdue Research Foundation | Microencapsulation of drugs by solvent exchange |
TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
US20080026068A1 (en) * | 2001-08-16 | 2008-01-31 | Baxter Healthcare S.A. | Pulmonary delivery of spherical insulin microparticles |
CA2481979A1 (en) | 2002-04-11 | 2003-10-16 | Yasushi Taguchi | Peptides chemically modified with polyethylene glycol |
MXPA05000797A (es) | 2002-07-24 | 2005-04-19 | Hoffmann La Roche | Polipeptidos t20 pegilados. |
WO2004022004A2 (en) | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
ATE361761T1 (de) | 2002-09-27 | 2007-06-15 | Hoffmann La Roche | Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4 |
MXPA05007348A (es) | 2003-01-06 | 2005-10-05 | Nektar Therapeutics Al Corp | Derivados de polimeros solubles en agua tiol-selectivos. |
WO2004093823A2 (en) * | 2003-03-19 | 2004-11-04 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
EP1613272B1 (en) * | 2003-04-11 | 2013-12-18 | Antriabio, Inc. | Method for preparation of site-specific protein conjugates |
PL1635875T3 (pl) | 2003-06-26 | 2009-03-31 | Psivida Inc | System dostarczania leków poprzez żelowanie w warunkach in-situ |
JP5165239B2 (ja) * | 2003-07-15 | 2013-03-21 | ピーアール ファーマシューティカルズ, インコーポレイテッド | 制御放出処方物の調製のための方法 |
WO2005009357A2 (en) | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
KR101135244B1 (ko) | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
WO2005061701A1 (ja) | 2003-12-24 | 2005-07-07 | Shionogi & Co., Ltd. | タンパク質のポリマー複合体の製造方法 |
WO2005065239A2 (en) | 2003-12-31 | 2005-07-21 | Centocor, Inc. | Novel recombinant proteins with n-terminal free thiol |
CA2552677A1 (en) * | 2004-01-13 | 2005-07-28 | Vasogenix Pharmaceuticals, Inc. | Controlled release cgrp delivery composition for cardiovascular and renal indications |
KR20060029770A (ko) | 2004-10-04 | 2006-04-07 | 주식회사 펙스피어 | Glp-1의 선택적 peg 접합체 및 그 제조방법 |
ES2350852T3 (es) | 2005-05-13 | 2011-01-27 | Eli Lilly And Company | Compuestos glp-1 pegilados. |
EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
WO2007056362A2 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
WO2007084460A2 (en) | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
CA2637565A1 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
WO2007139997A2 (en) | 2006-05-26 | 2007-12-06 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Methods for site-specific pegylation |
MX2009000434A (es) * | 2006-07-11 | 2009-01-29 | Qps Llc | Composiciones farmaceuticas para la distribucion de liberacion sostenida de peptidos. |
CN101573133B (zh) | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
KR20120099371A (ko) | 2009-08-05 | 2012-09-10 | 피어이스 에이지 | 리포칼린 뮤테인의 조절 방출 제형 |
CA2775287A1 (en) | 2009-09-25 | 2011-03-31 | Vybion, Inc. | Polypeptide modification |
GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
EP2495258B1 (en) | 2009-10-29 | 2016-12-07 | Korea Advanced Institute Of Science And Technology | Catechol polyethylene glycol derivative and protein or peptide conjugates, and method for preparing same |
WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
JP2013543746A (ja) | 2010-10-21 | 2013-12-09 | ケーシーアイ ライセンシング インコーポレイテッド | デブリドマンハンドツール |
WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
KR101746686B1 (ko) | 2010-10-26 | 2017-06-15 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체 |
CN102786590A (zh) | 2011-05-19 | 2012-11-21 | 江苏豪森药业股份有限公司 | 分枝型peg修饰的glp-1类似物及其可药用盐 |
CA3012117A1 (en) | 2011-05-27 | 2012-12-06 | Baxalta Incorporated | Fusions of psa with serpins and other therapeutic proteins |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
MX2013015168A (es) | 2011-06-22 | 2014-03-31 | Univ Indiana Res & Tech Corp | Co-agonista del receptor de glucagon/glp-1. |
US8936784B2 (en) * | 2011-10-17 | 2015-01-20 | Poly-Med, Inc. | Absorbable in situ gel-forming system, method of making and use thereof |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
KR102302634B1 (ko) | 2013-09-13 | 2021-09-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제 및 이의 조성물 |
JP6572497B2 (ja) | 2013-12-18 | 2019-09-11 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物 |
US10046058B2 (en) * | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
-
2015
- 2015-11-30 US US14/954,591 patent/US10046058B2/en not_active Expired - Fee Related
- 2015-11-30 US US14/954,701 patent/US20160151511A1/en not_active Abandoned
- 2015-12-01 AU AU2015355180A patent/AU2015355180A1/en not_active Abandoned
- 2015-12-01 CN CN201580065730.2A patent/CN106999443A/zh active Pending
- 2015-12-01 JP JP2017528931A patent/JP2017536387A/ja not_active Ceased
- 2015-12-01 EP EP20166087.5A patent/EP3695831A1/en not_active Withdrawn
- 2015-12-01 CA CA2966207A patent/CA2966207A1/en not_active Abandoned
- 2015-12-01 WO PCT/US2015/063102 patent/WO2016089818A1/en active Application Filing
- 2015-12-01 MX MX2017006594A patent/MX2017006594A/es unknown
- 2015-12-01 RU RU2017122609A patent/RU2712644C2/ru not_active IP Right Cessation
- 2015-12-01 EP EP15864955.8A patent/EP3226844A4/en not_active Withdrawn
- 2015-12-01 KR KR1020177014177A patent/KR20170086049A/ko unknown
- 2015-12-01 BR BR112017011531A patent/BR112017011531A2/pt not_active IP Right Cessation
-
2018
- 2018-07-11 US US16/032,952 patent/US10702611B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10046058B2 (en) | 2018-08-14 |
EP3226844A1 (en) | 2017-10-11 |
US20160151510A1 (en) | 2016-06-02 |
KR20170086049A (ko) | 2017-07-25 |
RU2712644C2 (ru) | 2020-01-30 |
BR112017011531A2 (pt) | 2018-02-27 |
AU2015355180A1 (en) | 2017-05-25 |
EP3226844A4 (en) | 2018-06-20 |
US10702611B2 (en) | 2020-07-07 |
EP3695831A1 (en) | 2020-08-19 |
RU2017122609A3 (es) | 2019-07-17 |
CA2966207A1 (en) | 2016-06-09 |
US20160151511A1 (en) | 2016-06-02 |
WO2016089818A1 (en) | 2016-06-09 |
CN106999443A (zh) | 2017-08-01 |
US20180318429A1 (en) | 2018-11-08 |
RU2017122609A (ru) | 2019-01-09 |
JP2017536387A (ja) | 2017-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017006594A (es) | Proteinas y congujados proteinicos con efecto hidrofobo aumentado. | |
EP3636656A4 (en) | PROCESS FOR SYNTHESIS OF A PEPTIDE CONTAINING AN N-SUBSTITUTED AMINO ACID | |
EP3735259A4 (en) | DECODING PROTEIN IDENTIFICATION METHOD | |
MX2019006043A (es) | Proteína de unión de antígeno prostático específico de membrana. | |
BR112017011662A2 (pt) | parceiros de fusão para a produção de peptídeo | |
EP3273793A4 (en) | Amino acid animal feed composition | |
MX2017001619A (es) | Encapsulacion de compuestos hidrofobicos biologicamente activos. | |
ZA201905674B (en) | Low ph pharmaceutical composition comprising t cell engaging antibody constructs | |
EA201790378A1 (ru) | Заключенное в липосому аффинное лекарственное средство | |
WO2016210365A3 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
MX363123B (es) | Produccion de productos de la proteina de leguminosa con astringencia reducida. | |
WO2015054590A3 (en) | NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PYRIDYL TETRAZINE | |
MX2016016886A (es) | Anticuerpos anti-axl. | |
MX2016014824A (es) | Proteinas biologicas condicionalmente activas. | |
MX2017005199A (es) | Conjugados y reactivos de conjugacion. | |
WO2014160490A8 (en) | Antibody formulations | |
CY1123425T1 (el) | Ειδικα για ton rsv αντισωματα και λειτουργικα τμηματα αυτων | |
BR112014027239A2 (pt) | peptídeo, método de identificação de peptídeos, método para o tratamento de câncer, nucleotídeo, vetor, uso de um peptídeo e invenção | |
EP3013789A4 (en) | Amino acid and peptide conjugates and conjugation process | |
MX2017003121A (es) | Formulaciones de anticuerpos. | |
EP3281627A4 (en) | Soluble microneedle for delivering proteins or peptides | |
PH12017500047A1 (en) | Dual cistronic bacterial expression system | |
EA201591678A1 (ru) | Антиперспирантные композиции | |
TW201613631A (en) | Ghrelin secretion promoter | |
IL261112A (en) | Conjugations of amino acid and peptide and conjugation process |